Femasys to Launch FemaSeed® and FemVue® in Israel Through AMI Partnership
Femasys has formed a partnership with AMI Technologies to launch its FemaSeed® intratubal insemination and FemVue® ultrasound diagnostics across Israeli fertility centers, leveraging AMI’s commercial network. The collaboration aims to drive physician adoption and expand international market access for Femasys’ fertility portfolio in a market with strong advanced reproductive demand.
1. Strategic Partnership Established
Femasys has entered into a strategic collaboration with AMI Technologies to commercialize its fertility portfolio in Israel, leveraging AMI’s established infrastructure and market expertise to support efficient entry into key fertility centers.
2. Product Rollout Plans
Under the partnership, FemaSeed® will be positioned as a first-line treatment ahead of intrauterine insemination, while FemVue® ultrasound diagnostics will enable tubal factor assessment, targeting physician adoption across leading Israeli fertility clinics.
3. Market Opportunity in Israel
Israel’s high per capita fertility treatment rates and advanced reproductive technology adoption make it a priority market; Femasys aims to capitalize on this environment to drive international revenue growth.
4. Expansion and Future Prospects
Femasys anticipates that this partnership will enhance global adoption of its fertility technologies, complement its U.S. commercial efforts, and serve as a model for further expansions into other high-demand reproductive health markets.